Tag Archives: Adverse Effects

Antidepressants Not Recommended for Depression in People With Dementia (NIHR Signal / Cochrane Database)

Posted on January 12, 2019 by Dementia and Elderly Care News

Summary A National Institute for Health Research “Signal” expert commentary refers to a systematic review which indicates that antidepressants are unsuitable / unhelpful for the treatment of depression in persons living with dementia. Full Text Link Reference Antidepressants do not … Continue reading →

Posted in Acute Hospitals, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, NIHR, Person-Centred Care, Pharmacological Treatments, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged Addenbrooke), Addenbrookes Hospital, Adverse Effects, Adverse Events, ALOIS: a Comprehensive Register of Dementia Studies, ALOIS: Cochrane Dementia and Cognitive Improvement's Specialized Register, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Antidepressants, Antidepressants for Agitation and Psychosis in Dementia, Antidepressants for Depression in Dementia, Antidepressants for Treating Depression in Dementia, Cambridge and Peterborough NHS Foundation Trust, Cambridge University Hospitals (Addenbrooke’s), Cochrane Database, Cochrane Database of Systematic Reviews, Cochrane Dementia and Cognitive Impairment Group, Cochrane UK, Department of Psychiatry: University of Cambridge, Drug Side-Effects, Inappropriate Medication, Inappropriate Prescribing, Later Life, Mental Health and Illness, National Institute for Health Research Signal, National Perinatal Epidemiology Unit (NPEU): University of Oxford, NIHR Signal, Older People’s Mental Health Service: Cambridge and Peterborough NHS Foundation Trust, Oxford Health NHS Foundation Trust, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing, Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Depression and Dementia, Preventable Adverse Events, Professor Martin Orrell, Professor Martin Orrell: Director of Institute of Mental Health at University of Nottingham; Division of Psychiatry and Applied Psychology: University of Nottingham, Psychotropic Drug Use (Antipsychotics Antidepressants Hypnotics Anxiolytics Anticonvulsants Antidementia Drugs), Reducing Inappropriate Prescribing of Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs), University of Cambridge, University of Nottingham, University of Oxford | Leave a comment

Dementia Medication De-Listed in France: Untruth, Half-Truth or Paternalistic News Blackout? (BBC News / Prescrire / ADI / Inside Health / JAMA Network Open)

Posted on October 18, 2018 by Dementia and Elderly Care News

Summary Early evening headlines yesterday, on BBC Radio 4 news, announced the “shocking” news that drugs for Alzheimer’s Disease / dementia had been de-listed in France. This story has not been followed-up, and appears to have been dropped quietly; although … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Universal Interest | Tagged Adverse Drug Reactions, Adverse Effects, Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR), Alzheimer's Disease: Monotherapy Versus Combination Therapy, Alzheimer's Research and Therapy, Alzheimer’s Disease International (ADI), Alzheimer’s Disease International (ADI) Campaigns, American Family Physician, Anti-Dementia Medication, Augusta University, BBC Radio 4, BBC Radio 4's Inside Health Programme, BBC Radio 4’s PM Programme, Big Pharma, BMJ, BMJ Publishing Group Ltd, British Medical Journal (BMJ), Cambridge Institute of Public Health: University of Cambridge, Care of the Elderly Medicine Department: Royal Wolverhampton NHS Trust, Cholinergic-Nicotinic System, Choosing Wisely, Clinic for Medicine of the Elderly (Hannover), Conflict of Interests, Conflicts of Interest, Department of Behavioral Neuroscience and Drug Development: Polish Academy of Sciences, Department of Psychiatry and Behavioral Health: Marshfield Clinic Health System, Department of Psychiatry and Behavioral Sciences: George Washington University School of Medicine and Health Sciences, Department of Psychiatry and Health Behavior: Augusta University, Department of Public Health and Primary Care: University of Cambridge, Deprescribing, Donepezil, Donepezil-Memantine Combination, Donepezil-Memantine: Monotherapy Versus Combination Therapy, Drug Efficacy, Drug Side-Effects, Drugs Alleged to Raise False Hopes (Speculative Construct), Family Medicine Residency Program: Southern Illinois University School of Medicine, Family Physicians Inquiries Network (FPIN), Formindep: Non-Profit Organisation Promoting Independence From Industry Influence, France, France's National Authority for Health (HAS), French Ministry of Health and Solidarity, French National Dementia Guidelines, Galantamine, Galantamine-Memantine Combination Versus Donepezil-Memantine Combination, Galantamine-Memantine Drug Combination, George Washington University School of Medicine and Health Sciences, Germany, Glutamatergic Receptor Systems, Glutamatergic System, Harms of Too Much Medicine, Institute of Pharmacology: Polish Academy of Sciences, JAMA Network Open, Janssen Research and Development, Journal of Geriatric Care and Research (JGCR), Keck School of Medicine: University of Southern California, KYNA/3-HK, KYNA/KYN, KYNA/QUIN, Kynurenic Acid, Kynurenine Pathway, Marshfield Clinic Health System (USA), Medical College of Georgia: Augusta University, Memantine, Ministry of Health and Solidarity (France), Mismatch Negativity (MMN), Mount Sinai Medical Center (New York), National Institutes of Health (NIH), National Institutes of Health (US), Neurotransmitter Systems in Alzheimer’s Disease, New Cross Hospital, New Cross Hospital: Royal Wolverhampton NHS Trust, NMDA (N-Methyl-D-Aspartate), Over-Treatment, Oxidative Stress, Paola Barbarino: Alzheimer’s Disease International, Poland, Polish Academy of Sciences, Prescrire in English [the Prescriber] / Rev. Prescrire, Reducing Waste in Dementia Care, Reducing Waste in the NHS, Rivastigmine, Royal Wolverhampton NHS Trust, Serge Gauthier: ADI’s Medical and Scientific Advisory Panel (MSAP), Society of Biological Psychiatry (SOBP), Southern Illinois University, Southern Illinois University School of Medicine, Synaptec Inc (Florida), Too Much Medicine, United States, University of Alabama at Birmingham, University of Cambridge, University of Southern California, USA | Leave a comment

Aspirin: Stomach Bleeds Risk for Over-75s (BBC News / Lancet / NHS Choices)

Posted on June 15, 2017 by Dementia and Elderly Care News

Summary Persons aged over 75 taking daily aspirin following a stroke or heart attack are at higher risk of stomach bleeds than thought previously. The benefits of low dose aspirin still outweigh the risks, even in this age group. Co-prescription … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged adverse, Adverse Drug Events, Adverse Drug Reactions (ADRs), Adverse Drug Reactions in the Elderly, Adverse Effects, Adverse Events, Aspirin, Aspirin: Low-Dose Acetylsalicylic Acid, Aspirin: Stomach Bleeds Risk for Over-75s, BBC Health News, Behind the Headlines, Centre for Prevention of Stroke and Dementia: University of Oxford, Daily Low-Dose Aspirin, Gastrointestinal Bleeding, John Radcliffe Hospital, Lancet, Nuffield Department of Clinical Neurosciences: University of Oxford, Oxford Vascular Study, Oxford Vascular Study (OXVASC), Prophylactic Use of Aspirin, Proton Pump Inhibitors (PPIs), University of Oxford | Leave a comment

Introducing the Journal of Geriatric Care and Research (JGCR)

Posted on July 3, 2016 by Dementia and Elderly Care News

Summary The Journal of Geriatric Care and Research (ISSN 2397-5628) is a recently launched, locally edited, multi-disciplinary peer-reviewed international journal, which covers topics of relevance to the care of the elderly. Concerning Guidelines on the Use of Antipsychotics for Agitation … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, International, Local Interest, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Wales, Wolverhampton | Tagged Academia.edu, Adverse Drug Reactions (ADRs), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Agitation, Agitation and Aggression, Alternatives to Antipsychotics, Alzheimer’s Disease-Related Agitation, American Journal of Psychiatry, American Psychiatric Association (APA), American Psychiatric Association: Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia (2016), Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, APA Practice Guidelines, Aripiprazole, Atypical Antipsychotics, Avoidable Harm, Avoidable Hospital Mortality, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Benefits and Risks of Antipsychotic Treatment, Betsi Cadwaladr University Health Board, Black Country, Black Country Partnership NHS Foundation Trust, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, British Indian Psychiatric Association (BIPA), Community and Mental Health Trusts, Dr Sarmishtha Bhattacharyya: Consultant in Old Age Psychiatry at Wrexham Maelor Hospital, Faculty of Health and Social Care: University of Chester, Geriatric Care and Research Organisation (GeriCaRe), Haloperidol, Improving Prescribing Practice, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, Journal of Geriatric Care and Research (JGCR), Learning Disabilities, Medication Reviews, Mental Health Trusts, North Wales, Olanzapine, Over-Medication, Over-Medication for People With Learning Disabilities, Over-Prescribing, Overprescribing, People With Learning Disabilities, Personalised Care Versus Guideline-Based Care, Personalised Medicine Versus Guideline-Based Medicine, Potential Harms of Antipsychotic Use, Potentially Inappropriate Prescribing, Prescribing Anti-Psychotic Drugs to People with Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Prescribing of Antipsychotic Drugs For People With Learning Disabilities, Psychosis in Patients With Dementia, Quetiapine, Reducing Agitation and Distress, Reducing Antipsychotic Prescriptions in Dementia, Reducing Avoidable Premature Mortality, Reducing Inappropriate Use of Antipsychotics, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Safe and Compassionate Care, United States, University of Chester, USA, Violence and Aggression, West Midlands, Wrexham, Wrexham Maelor Hospital, Ziprasidone | Leave a comment

Reducing Antipsychotic Prescribing for BPSD (BMJ / JAMA / JAMA Psychiatry / BJCP)

Posted on November 6, 2014 by Dementia and Elderly Care News

Summary This BMJ “Change page” article discusses the potential harms associated with use of antipsychotics in people with dementia, and covers guidelines recommending restrictions in their use. Risperidone is the antipsychotic recommended for use in the treatment of aggression associated … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, Statistics, UK | Tagged Adverse Drug Reactions (ADRs), Adverse Drug Reactions (ADRs): Type A (Potentially Avoidable and Associated With Commonly Prescribed Medications), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Alternatives to Antipsychotics, Antidepressants, Antihypertensives, Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Absolute Mortality Risk Increase, Antipsychotics: Neuroleptic Sensitivity, Antipsychotics: Number Needed to Harm (NNH), Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, BMJ, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Brief Psychosocial Treatment, British Journal of Clinical Pharmacology, British Medical Journal (BMJ), Campbell Institute (CAMH): University of Toronto, Cardiff University, Center for Clinical Management Research: Veterans Affairs Ann Arbor Healthcare System (Michigan), Center for Statistical Consultation and Research: University of Michigan, CitAD Research Group, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Clinical Biotechnology Research Institute: Roper St Francis Healthcare (Charleston: South Carolina), College of Physicians and Surgeons of Columbia University, DART-AD: Dementia Antipsychotic Withdrawal Trial (DART-AD), Dementia Antipsychotic Withdrawal Trial (DART-AD), Department of Psychiatry: University of Michigan, Department of Psychiatry: University of Southern California, Discontinuation of Antipsychotics, Effect of Citalopram on Agitation in Alzheimer Disease (CitAD Randomized Clinical Trial), Falls Prevention, Hotchkiss Brain Institute: University of Calgary, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, International Conference on Harmonization, JAMA, JAMA Psychiatry, Johns Hopkins Bayview and Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health: Baltimore, Kings College London, Medication Reviews, National Institute for Health Research (NIHR): Mental Health Biomedical Research Centre and Dementia Unit, NEST Approach, Neuroleptic Discontinuation, Neuroleptics, New York State Psychiatric Institute, Patients’ Needs and the Environment Stimulation and Techniques (NEST), Perelman School of Medicine: University of Pennsylvania, Personalised Social Interaction, Pharmacokinetics, Polypharmacy, Potential Harms of Antipsychotic Use, Prescribing Anti-Psychotic Drugs to People with Dementia, Reducing Agitation and Distress, Reducing Antipsychotic Medication in Care Homes, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Seattle Protocols, Simulated Presence Therapy, South London and Maudsley NHS Foundation Trust, Stanford University School of Medicine, United States, University Hospital Llandough (Cardiff), University of Calgary, University of Manchester, University of Michigan, University of Pennsylvania, University of Rochester School of Medicine and Dentistry, University of Southern California, University of Southern California Keck School of Medicine, University of Toronto, Violence and Aggression, Wolfson Centre for Age-Related Diseases: King’s College London | Leave a comment

Statins: Effective, Affordable and Acceptable Risk-Benefit Profile (BBC News / NICE / BMJ / BMC Medicine)

Posted on July 19, 2014 by Dementia and Elderly Care News

Summary According to latest guidelines from the National Institute for Health and Care Excellence (NICE), four out of ten adults in England, Wales and Northern Ireland will be eligible for statins; even though they are at relatively low risk of … Continue reading →

Posted in Acute Hospitals, BBC News, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, National, NHS, NICE Guidelines, Northern Ireland, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Scotland, Standards, Statistics, Stroke, Systematic Reviews, UK, Universal Interest, Wales | Tagged Adherence to Statin Therapy, Adverse Effects, Alcohol Consumption, Atorvastatin, BBC Health News, BMC Medicine, BMJ, British Medical Association's General Practitioner Committee, British Medical Journal (BMJ), Cancer, Cardioprotective Diet, Cardiovascular Disease, Cardiovascular Risk, Cataracts, Cholesterol, Cholesterol Levels, Cholesterol-Lowering Drugs, Cholesterol-Lowering Medications, Chronic Obstructive Pulmonary Disease, Cognition, Cognitive Decline, Cognitive Impairment, Combined Interventions (Diet and Physical Activity), Concerns Over Statins Use, COPD, Costs of Statins (Declining), County Hospital (Hereford), CVD Risk Assessment, CVD: Cardiovascular Disease, Department of Geriatric Medicine: County Hospital (Hereford), Diabetes, Drug Side-Effects, Erectile Dysfunction, Evidence-Based Medicine, Eyes and Vision, Fatigue, Fluvastatin, Grouping of Statins (Three Intensity Categories), Harvard Medical School, Healthy Lifestyles, Hepatotoxicity, Informed Choice, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, JUPITER Study, Kidney Disorders, Lifestyle Modifications for Primary and Secondary Prevention of CVD, Lifestyle Risk Factors, Lifestyle Weight Management, Lipid Lowering and Onset of Renal Disease (LORD) Study, Lipid Modification, Lipophilic Statins, Liver Disorders, Liver Toxicity, London School of Hygiene and Tropical Medicine, Low Density Lipoprotein Cholesterol (LDL-C), Mass Prescription, MCI: Mild Cognitive Impairment, Memory Lapses, Memory Loss, Memory Problems, Mild Cognitive Impairment (MCI), Misinformation About Statins (Historical), Modifiable Risk Factors, Muscle Toxicity, Musculo-Skeletal Disorders, Myopathy, National Institute for Health and Care Excellence (NICE), Neurological Disorders, Neuronal Cell Membranes, NHS Choices Health A-Z Information on Statins, NHS Choices: Healthy Cooking, NHS Choices: Healthy Diet, NHS Choices: Healthy Eating, NHS Choices: Physical Activity, NHS Health Checks Programme, NICE Clinical Guideline CG181, NICE Clinical Guideline CG67, Non-Cardiovascular Effects Associated With Statins, Non-Cardiovascular Harms of Statins, Non-Cardiovascular Side-Effects of Statins, Off-Label Use, Over-Medicalisation (Speculative Concept), Overdiagnosis (Speculative Concept), Overtreatment (Speculative Concept), Pancreatitis, Patient Choice, Patient-Doctor Discussion, Physical Activity, Physical Activity Prescriptions, Physical Activity Programmes, Potential Harms Associated With Statins, Pravastatin, Preventative Mass Prescription, Prospective Study of Pravastatin in the Elderly (PROSPER) Trial, QRISK2 Assessment Tool, QRISK2 Calculator, Renal Disorders, Respiratory Disorders, Rhabdomyolysis, Risk Factors, Risk Factors of Stroke, Rosuvastatin, Scandinavian Simvastatin Survival Study, Simvastatin, Smoking Cessation, Smoking Cessation Services, Statin Induced Myopathy, Statins, Statins for Stroke Prevention in Older Patients, Statins: Contraindicated in Pregnancy, Statins: Few Contraindications, Statins: Risk-Benefit Profile, Stroke Prevention in Older Patients, Stroke Risk Factor Modification, Unintended Effects of Statins, Urological Disorders, Use of Drugs Outside Their Licensed Indications, Use of Statins, Venous Thromboembolism, Weight Management | Leave a comment

Pharmacological Treatments for Neuropsychiatric Symptoms in Alzheimer’s Disease (Journal of Neurology Neurosurgery and Psychiatry)

Posted on June 25, 2014 by Dementia and Elderly Care News

Summary This systematic review investigates the efficacy and safety of various pharmacological treatments for neuropsychiatric symptoms in Alzheimer’s Disease patients. It concludes that cholinesterase inhibitors (ChEIs) and atypical antipsychotics could improve neuropsychiatric symptoms in these patients, but with poor patient … Continue reading →

Posted in Antipsychotics, Depression, For Doctors (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Systematic Reviews | Tagged Adverse Drug Reactions, Adverse Effects, Adverse Events, Antidepressants, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, Benzodiazepines for BPSD, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Cerebrovascular Adverse Events, ChEIs: Cholinesterase Inhibitors, China, Cholinesterase Inhibitors, Journal of Neurology Neurosurgery and Psychiatry, Memantine, Mood Stabilisers, Nanjing Medical University, Neuropsychiatric Inventory (NPI), Neuropsychiatric Symptoms in Alzheimer’s Disease, Patient Safety, Pharmacological Treatments for Neuropsychiatric Symptoms in Alzheimer’s Disease, Qingdao Municipal Hospital, Qingdao University, Serious Adverse Events, Shandong Province, Systematic Reviews and Meta-Analyses | Leave a comment

Tag Archives: Adverse Effects

Antidepressants Not Recommended for Depression in People With Dementia (NIHR Signal / Cochrane Database)

Dementia Medication De-Listed in France: Untruth, Half-Truth or Paternalistic News Blackout? (BBC News / Prescrire / ADI / Inside Health / JAMA Network Open)

Aspirin: Stomach Bleeds Risk for Over-75s (BBC News / Lancet / NHS Choices)

Statins: Effective, Affordable and Acceptable Risk-Benefit Profile (BBC News / NICE / BMJ / BMC Medicine)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites